Incyte Corporation (NASDAQ:INCY) generated buzz on August 19 when RBC Capital highlighted upcoming ESMO data for its KRAS G12D inhibitor ‘734 in combination with mFOLFIRINOX and GemNabP. RBC noted that while prior data was too limited for firm conclusions, the update should look “very competitive” and support ongoing Phase 3 efforts in first-line pancreatic ductal adenocarcinoma (1L PDAC). RBC added that ‘734 appears comparable to Revolution Medicines, Inc. (NASDAQ:RVMD)’s zoldonrasib, holding a Sector Perform rating and $109 target.
RVMD, however, delivered landmark operational milestones. On August 21, Bernstein raised RVMD’s price target from $151 to $179 (Market Perform), expressing optimism over its PDAC launch and non-small cell lung cancer (NSCLC) development. Bernstein did caution against long-term competition and potential colorectal cancer underperformance.
The main breakthrough arrived on August 26: the FDA approved Revolution’s Rasonque (once-daily oral tablet) for adults with metastatic pancreatic adenocarcinoma previously treated or ineligible for multiagent chemotherapy. Rasonque marks the first targeted cancer medicine approved from a new class of RAS(ON) multi-selective and mutant-selective inhibitors. The approval was backed by the Phase 3 RASolute 302 trial, which hit all primary and key secondary endpoints in both RAS G12 mutant and intent-to-treat populations.
Financial Performance: Revenue Commercial Engine vs. High-Burn Balance Sheet
Financially, the two companies present stark operational profiles. In Q2 2026, Incyte Corporation (NASDAQ:INCY) generated $1.67 billion in total revenue (+38% YoY) and $1.49 billion in net sales (+40% YoY). Growth was driven by its core Jakafi franchise ($817 million, +7% YoY) and Opzelura ($450 million, +173% YoY). Although Opzelura benefited from a one-time $246 million CMS settlement benefit, underlying product demand remained robust. Incyte posted GAAP net income of $585.6 million ($2.92 EPS), raised full-year net sales guidance to $5.13B–$5.26B, and held $4.5 billion in cash and equivalents.
Conversely, Revolution Medicines, Inc. (NASDAQ:RVMD) reported zero product revenue in Q2 2026 as it prepared for commercialization. Net loss widened to $644.4 million ($3.06 per share), driven by $394.9 million in R&D and $110.2 million in G&A expenses supporting late-stage trials and launch preparations. Full-year 2026 GAAP operating expense guidance stands at $2.1B–$2.2B. However, RVMD boasts a formidable balance sheet with $3.9 billion in cash, cash equivalents, and marketable securities, bolstered by $2.225 billion in gross financing proceeds and a $250 million Royalty Pharma payment.
Bull and Bear Cases
Incyte’s bull case is supported by its highly profitable commercial foundation, particularly Jakafi and Opzelura, which generates sufficient cash flow to fund pipeline development such as ‘734 without requiring dilutive capital raises. However, the bear case centers on its reliance on mature products, potential loss-of-exclusivity risks, and the possibility that non-recurring benefits could make near-term financial performance appear stronger than its underlying trajectory.
Revolution Medicines’ bull case is driven by its first-mover position in RAS(ON) innovation, including its FDA-approved Rasonque, supported by a substantial $3.9 billion cash buffer that provides financial flexibility for continued development. On the downside, accelerating operating expenses of $2.1 billion to $2.2 billion could sustain significant cash burn, while emerging targeted competition in pancreatic ductal adenocarcinoma (PDAC) and lung cancer may challenge its long-term market opportunity.
Insider Monkey’s Hedge Fund Data Analysis
Institutional smart money heavily favors Revolution’s upside potential. In Q2 2026, 105 hedge funds held RVMD (down slightly from 106 in Q1). Notable holders include Thomas Steyer’s Farallon Capital (13.55M shares, $2.54B, 11.71% of portfolio) and Julian & Felix Baker’s Baker Bros. Advisors, who boosted their stake by 20% to 11.44M shares ($2.14B, 10.74% of portfolio).
In contrast, Incyte saw 45 fund holdings in Q2 2026 (up from 42 in Q1). Baker Bros. Advisors remains the top holder with 30.76M shares ($3.49B, 17.48% of portfolio), while Cliff Asness’s AQR Capital Management trimmed its stake by 9% to 5.32M shares ($603.2M, 0.21% of portfolio).
Conclusion: What Investors Should Watch Next
Investors must track whether Revolution Medicines, Inc. (NASDAQ:RVMD) can execute a smooth commercial rollout for newly approved Rasonque while managing its high operating burn. For Incyte Corporation (NASDAQ:INCY), the October ESMO data release for ‘734 will reveal whether its KRAS inhibitor can truly challenge Revolution’s footprint in 1L PDAC.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center